

## Accepted Manuscript

Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy

Yongju He, Zhigui Su, Lingjing Xue, Hui Xu, Can Zhang

PII: S0168-3659(16)30113-4  
DOI: doi: [10.1016/j.jconrel.2016.03.001](https://doi.org/10.1016/j.jconrel.2016.03.001)  
Reference: COREL 8162

To appear in: *Journal of Controlled Release*

Received date: 3 December 2015  
Revised date: 4 February 2016  
Accepted date: 1 March 2016



Please cite this article as: Yongju He, Zhigui Su, Lingjing Xue, Hui Xu, Can Zhang, Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy, *Journal of Controlled Release* (2016), doi: [10.1016/j.jconrel.2016.03.001](https://doi.org/10.1016/j.jconrel.2016.03.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy

Yongju He<sup>a</sup>, Zhigui Su<sup>b</sup>, Lingjing Xue<sup>b</sup>, Hui Xu<sup>a,b\*</sup>, Can Zhang<sup>b\*\*</sup>

<sup>a</sup>Lab of Nano-biology Technology, School of Physics and Electronics, Central South University, Changsha, Hunan 410083, China

<sup>b</sup>State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, ~~Center of Drug Discovery~~, China Pharmaceutical University, Nanjing 210009, China

## Abstract

Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize their apoptotic response to DNA damage agent doxorubicin (DOX). To translate this synergistic therapy into in vivo anticancer therapy and clinical practice, we designed a novel pH-sensitive charge conversion nanocarrier (M-HHG<sub>2</sub>C<sub>18</sub>-L) that contained erlotinib/DOX combination and produced a sequential staggered drug release for synergistic lung cancer therapy. In this study, a synthetic zwitterionic oligopeptide lipid (1,5-dioctadecyl-L-glutamyl2-histidyl-hexahydrobenzoic acid, HHG<sub>2</sub>C<sub>18</sub>) was used to construct a pH-sensitive lipid bilayer (HHG<sub>2</sub>C<sub>18</sub>-L), which was subsequently applied to coat amino-functionalized mesoporous silica nanoparticles (MSN-NH<sub>2</sub>). Erlotinib and DOX were separately incorporated into HHG<sub>2</sub>C<sub>18</sub>-L and MSN-NH<sub>2</sub> respectively to obtain pH-sensitive charge conversion erlotinib/DOX co-delivery nanoparticles

---

\* Corresponding author: xuhui@csu.edu.cn

\*\* Corresponding author: zhangcan@cpu.edu.cn

Download English Version:

<https://daneshyari.com/en/article/7861965>

Download Persian Version:

<https://daneshyari.com/article/7861965>

[Daneshyari.com](https://daneshyari.com)